Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis
Journal of Psychopharmacology · 2023
DOI: 10.1177/02698811221148604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Psychopharmacology, 2023. Verfasst von Anahita Bassir Nia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Cannabis, Psychotic Disorders, Hallucinogens. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: NIDA NIH HHS, NCATS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Cannabis use suppresses the endocannabinoid system in healthy individuals. However, the association between cannabis use with the endocannabinoid system is understudied in individuals with psychosis despite the high rate of cannabis use in these individuals.
Methods
We enrolled 83 individuals who were admitted to an inpatient psychiatric unit with psychotic presentations, and measured their plasma levels of main endocannabinoids, Anandamide (AEA) and 2-Acylglycerol (2-AG), and endocannabinoid related compounds, Palmitoylethanolamine, and N-oleoylethanolamine. Cannabis use was assessed with urine toxicology and frequency of cannabis use was assessed using self-reported questionnaires. The Positive and Negative Syndrome Scale was used to assess the severity of psychotic symptoms.
Results
Overall, we had 38 individuals in cannabis positive group (CN+) and 45 individuals in cannabis negative group (CN−). Compared to CN−, CN+ group had lower plasma levels of AEA, which remained significant after controlling for age, gender, race/ethnicity, and use of other drugs.
Conclusion
Cannabis use is associated with low plasma AEA levels in individuals with psychosis, which is in the same line with reported suppressive effects of cannabis on the endocannabinoid system in healthy individuals. Further studies are needed to investigate the clinical significance of this finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
- Center for Drug Discovery, Northeastern University, Boston, MA, USA.
- Addiction Institute at Mount Sinai, New York City, NY, USA.
ORCID-Profile: Anahita Bassir Nia
Förderung
- NIDA NIH HHS
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Bassir Nia, A., Gibson, C. L., Spriggs, S. A., Jankowski, S. E., DeFrancisco, D., Swift, A., Perkel, C., Galynker, I., Honrao, C., Makriyannis, A., & Hurd, Y. L. (2023). Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221148604
Vancouver
Bassir Nia A, Gibson CL, Spriggs SA, Jankowski SE, DeFrancisco D, Swift A, et al. Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. Journal of Psychopharmacology. 2023. doi:10.1177/02698811221148604
BibTeX
@article{BassirNia2023,
author = {Bassir Nia, Anahita and Gibson, Claire L and Spriggs, Sharron A and Jankowski, Samantha E and DeFrancisco, Daniel and Swift, Amy and Perkel, Charles and Galynker, Igor and Honrao, Chandrashekhar and Makriyannis, Alexandros and Hurd, Yasmin L},
title = {Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis},
journal = {Journal of Psychopharmacology},
year = {2023},
doi = {10.1177/02698811221148604}
}
EUVIMED